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doi:10.1Objective: Pulmonary fibrosis is a life-threatening disease that results in progressive respiratory failure. We
have suggested the possibility of fetal lung tissue as an option for further investigation into lung regeneration.
The objective was to prove whether fetal lung fragments can survive and differentiate in fibrotic lung.
Methods: Lewis rats were administered bleomycin and used as recipients after 3 or 4 weeks. Day 17 fetal lung
tissue from green fluorescent protein Lewis rats was used as donor material. Donor lungs were removed, cut into
small pieces, and implanted into the recipients’ left lung. The recipients received cyclosporin to prevent immune
response to green fluorescent protein and were killed after 1, 2, 4, 8, and 12 weeks and histologically evaluated.
Furthermore, the expression of thyroid transcription factor-1 and Clara cell secretory protein in the implanted
fetal lung tissue was immunohistologically evaluated.
Results: Fibrotic changes were recognized for a long period of time in the recipient lungs. The implanted fetal
lung fragments could be clearly distinguished from recipient lungs because of the luminescence of grafts. Fetal
lung fragments could survive in the recipient lungs with fibrotic changes. The air spaces of implanted fetal lungs
were narrow at 1 and 2 weeks but expanded with the passage of time. The connection between the recipient lung
and the implanted fetal lung was recognized, particularly in the peripheral grafts. The expression patterns of thy-
roid transcription factor-1 and Clara cell secretory protein in implanted lungs resembled those in the process of
normal lung morphogenesis.
Conclusions: Fetal rat lung fragments could survive and differentiate in bleomycin-induced completely fibrotic
lung. (J Thorac Cardiovasc Surg 2012;143:1429-35)/B
SIdiopathic pulmonary fibrosis is a chronic progressive and
potentially fatal lung disease characterized by the prolifer-
ation of fibroblasts and deposition of extracellular matrix.1,2
Kim and colleagues3 indicated that its prognosis was poor
and that survival time from diagnosis ranged from 2 to 4
years. Although anti-inflammatory drugs such as predni-
sone and cytotoxic drugs (eg, cyclophosphamide and aza-
thioprine) are used for treatment, they do not halt the
progression of fibrosis or clearly improve lung function or
life expectancy.1,4 To date, although various drugs have
been used for clinical trials, none has shown success
comparable to that of antifibrotic drugs.4 At present, lung
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TSeveral potential sources of cells for airway epithelium
repair have been identified. These are divided into exoge-
nous stem cells from other tissue in the body and endoge-
nous progenitor cells present in the respiratory tract.5
Rojas and colleagues6 reported that bone marrow–derived
stem cells, which are an example of exogenous stem cells,
could integrate into alveolar epithelium and contribute to
lung regeneration in a model of bleomycin (BLM)-induced
pulmonary fibrosis. However, some studies have failed to
restore alveolar epithelium.7,8 Furthermore, although stem
cells such as embryonic stem cell–induced pluripotent
stem cells can also be expected as new sources for lung
regeneration, no direct applications to airway cells have
been reported.5 On the other hand, Serrano-Mollar and col-
leagues9 reported that transplantation of alveolar type II
cells, which are an example of endogenous progenitor cells,
reversed BLM-induced pulmonary fibrosis in rats. How-
ever, this was considered to be a limited method to prevent
the fibrotic process. As such, tissue engineering of the lung
with various cell sources is still difficult because of prob-
lems to select (1) the cell source with the highest potential,
(2) the best biocompatible and degradable scaffold suitable
for lung development, (3) the best combination of growth
factors and culture conditions to promote cellular differen-
tiation, and (4) the best conditions to support 3-dimensional
production of lung tissues.10diovascular Surgery c Volume 143, Number 6 1429
Abbreviations and Acronyms
BLM ¼ bleomycin
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GFP ¼ green fluorescent protein
OCT ¼ optimal cutting temperature
TTF-1 ¼ thyroid transcription factor-1




SOn the other hand, we have attempted lung regeneration
using fetal rat lung tissue as another approach.11 Fetal lung
tissue has (1) great potential for further growth, (2) excel-
lent potential for differentiation and proliferation, and (3)
mesenchymal tissue as a suitable scaffold.12 In a previous
study, we made use of its characteristics and investigated
whether fetal rat lung tissue implanted into adult lung pa-
renchyma could survive, grow further, and differentiate.
We could consequently suggest the possibility of fetal
lung tissue as an option for further investigation into lung
regeneration.11 In this study, we made a long-term model
of BLM-induced pulmonary fibrosis, implanted fetal rat
lung fragments into fibrotic lung, and investigated whether
the graft could survive.MATERIALS AND METHODS
Animals
This study was approved by the Animal Care Committee of the Univer-
sity of Tokushima. Specific pathogen-free male Lewis rats aged approxi-
mately 8 to 10 weeks were obtained from Charles River Japan, Inc
(Kanagawa, Japan) and used as recipients.
Green fluorescent protein (GFP) Lewis fetal rat lungs were used as do-
nors to clarify the borderline between donor and recipient. GFP Lewis
rats were provided by the Division of Organ Replacement Research, Cen-
ter for Molecular Medicine, Jichi Medical University School of
Medicine.13
Rats were maintained in an animal house in a pathogen-free environ-
ment, with a 12-hour light–dark cycle, and provided free access to water
and food. The animals received humane care in compliance with the insti-
tutional and national guidelines (Japanese Ministry of Education, Culture,
Sports, Science and Technology).
Bleomycin Hydrochloride–Induced Pulmonary
Fibrosis
BLM hydrochloride was purchased from Nippon Kayaku Co (Tokyo,
Japan). Intratracheal administration of BLM was performed according to
the method described by Goto and colleagues.14 Each rat was anesthe-
tized by an intraperitoneal injection of ketamine hydrochloride (20 mg/
kg) and diazepam (7.5 mg/kg), tracheostomy was surgically performed,
and a catheter made using a polyethylene tube (internal diameter 0.2
mm, outer diameter 0.5 mm; Natsume Seisakusho Co, Japan) beforehand
was inserted between the cartilaginous rings and placed in the trachea.
Then, the catheter was subcutaneously tunneled to the nape of the
neck. Three days after insertion of the catheter, BLM at a total dose of
4.5 mg/kg was administered in 4 separate doses (0.5 mL/kg/time) at inter-
vals of 2 hours to the rats via the catheter with 1.5% halothane
(N2O:O2 ¼ 1:1). Three to four weeks after administration of BLM, rats1430 The Journal of Thoracic and Cardiovascular Surwere used as recipients. Control animals received the same volume of
saline in the same manner.
Preparation of Donors
Female Lewis rats aged approximately 8 to 10 weeks were chosen and
mated with GFPmale Lewis rats for only 1 day. Seventeen days later, preg-
nant rats were killed. After their fetuses were removed, only GFP fetuses
with fluorescence by excitation light (ultraviolet A; 365 nm) were selected
and used. Both their lungs were dissected under a microscope, cut into fine
pieces, and stored in Dulbecco’s modified Eagle’s medium containing 10%
fetal bovine serum and penicillin-streptomycin (Life Technologies Corp,
Carlsbad, Calif).15
Implantation Procedure
BLM-administered rats were used as recipients. They were ventilated
with a small animal respirator (SN480-7, Shinano, Tokyo, Japan) at 70 cy-
cles/min, a tidal volume of 10 mL/kg, and a positive end-expiratory pres-
sure of 2 cm H2O under atropine sulfate at 0.1 mg/body (administered
subcutaneously) and 1.5% halothane (N2O:O2 ¼ 1:1). After left thoracot-
omy, GFP fetal lung fragments were injected just under the pleura of the
left lung apex, at a volume of 0.1 mL that contained lung fragments
from 2 fetuses, using a 0.25-mL syringe and 20-gauge needle. After im-
plantation, they immediately received 10 mg/kg cyclosporin A (CyA) (dis-
solved in olive oil and absolute alcohol and injected intramuscularly) to
prevent an immune response to GFP protein. In addition, they received 4
mg/kg CyA on the first day after implantation and subsequently 1 mg/kg
every other day until sacrifice. BLM-administered rats that received only
CyA by the same regimen were used as vehicle control.
Experimental Groups
Animals were randomly distributed into 4 groups: (1) saline group
(n¼ 24), saline administration; (2) BLM group (n¼ 24), BLM administra-
tion; (3) implantation group (n ¼ 20), BLM administration plus implanta-
tion of GFP fetal rat lung fragment and CyA administration; and (4) control
group (n ¼ 25), BLM administration and CyA administration.
In the saline and BLM groups, 6 animals were killed at 4, 8, 12, and 16
weeks. Four animals in the implantation group and 5 animals in the control
group were killed at 1, 2, 4, 8, and 12 weeks.Histologic Study
The lungs were perfused with saline through the pulmonary artery after
cutting the left atrium and then removed en bloc with the heart. In the
implantation group, they were fixed with fixing solution (4% paraformal-
dehyde: optimal cutting temperature [OCT] compound¼ 4:1) from the tra-
chea at 15 cm H2O. After the specimens were preserved at 4 degrees for
5 hours in a dark room and the position of donors was identified from fluo-
rescence by excitation light (ultraviolet A; 365 nm), theywere embedded in
OCT compound and preserved by freezing. Later, they were cut at 10-mm
thickness to observe non-stained histologic specimens under a fluorescence
microscope and finally embedded in paraffin. Their images were captured
using Biozero BZ-8000 (KEYENCE Co, Ltd, Osaka, Japan). In 3 other
groups, the lungs were fixed with the fixing solution (10% phosphate-
buffered formalin solution: OCT compound ¼ 4:1) at the same pressure
and embedded in paraffin. In all groups, paraffin-embedded sections
were cut at 4-mm thickness and stained with hematoxylin–eosin and Mas-
son trichrome. Light microscope images from histologic specimens were
captured using an Olympus BX51-FL (Olympus Co, Ltd, Tokyo, Japan).
Five fields at 403 magnification of the left lung of each animal were ob-
served under a light microscope. The score of each field was allotted,
and the mean score was calculated. Morphologic changes in fibrotic lungs
were quantified according to a numeric scale from 0 to 8 as described by
Ashcroft and colleagues.16 Briefly, the score was as follows: 0, normal;
1, minimal fibrous thickening; 2, minimal to moderate; 3, moderate; 4,gery c June 2012
Toba et al Evolving Technology/Basic Sciencemoderate or more; 5, increased fibrosis with definite damage; 6, moderate
structural distortion; 7, severe distortion of structure and large fibrous
areas; and 8, total fibrous obliteration.Immunohistochemistry
To examine the relationship between cell differentiation and morpho-
logic changes of implanted grafts, we performed immunohistochemical
staining with anti-thyroid transcription factor-1 (TTF-1) and anti-Clara
cell secretory protein (CCSP) antibody. Immunohistochemistry for TTF-1
and CCSP was performed as follows. After deparaffinization, sections
were incubated in 10 mmol/L citric buffer (pH 6) and heated for 10 minutes.
After nonspecific sites were blocked with phosphate-buffered saline contain-
ing 5% milk and 0.3% Triton X-100 (Wako Pure Chemical Industries,
Osaka, Japan), sections were incubated for 1 hour at room temperature
with primary antibodies. The primary antibodies used were as follows:
anti–TTF-1 mouse monoclonal antibody (1:50 dilution; clone 8G7G3/1,
Thermo Fisher Scientific, Fremont, Calif) and anti-CCSP rabbit polyclonal
antibody (1:50 dilution; SCGB1A1, LifeSpan BioSciences, Seattle, Wash).
After thorough washing in phosphate-buffered saline containing 0.1% Non-
idet P-40 (Nacalai Tesque Inc, Kyoto, Japan), sections were incubated with
appropriate secondary fluorescence-labeled antibodies for 30 minutes at
room temperature and stained with DAPI (Dojindo Laboratories, Kuma-
moto, Japan). Secondary antibodies used were as follows: ImmPRESS
anti-mouse Ig (1:500 dilution; Vector Laboratories, Burlingame, Calif)
and Cy3 for anti–TTF-1 and ImmPRESS anti-rabbit Ig (1:500 dilution; Vec-
tor Laboratories) and Alexa594 for anti-CCSP. Immunostaining fluores-
cence was observed, and images were captured using a Leica CW4000
system (Leica Microsystems Co, Ltd, Wetzlar, Germany).FIGURE 1. Histologic examination of BLM-induced pulmonary fibrosis. Rats
and 16 weeks, rats were killed and histologic examination was performed by he
images were taken at the same power (original magnification, 340). A-D, Salin
representative of 6 animals that were treated in the same way. E-L, Various fib
The Journal of Thoracic and CarStatistical Analysis
All values are expressed as mean standard deviation. Statistical anal-
yses were performed using the Student t test with SPSS version 11.0.1
(SPSS Inc, Chicago, Ill). In addition, differences in Ashcroft score at dif-
ferent time points were analyzed by 1-way repeated-measure analysis of
variance corrected for multiple comparisons by Bonferroni correction com-
paring all pairs of columns.
RESULTS
Histologic Changes and Evaluation of Fibrotic
Change in the Lung Using the Ashcroft Score after
Intratracheal Administration of Saline and
Bleomycin Hydrochloride
To evaluate whether our models were feasible as models
of pulmonary fibrosis for a long-term period ranging over
16 weeks, we first examined the histologic changes 4, 8,
12, and 16 weeks after intratracheal instillation of saline
and BLM. In the saline group, no histologic changes were
recognized at 4, 8, 12, and 16 weeks (Figure 1, A-D,
340). On the other hand, in the BLM group, various find-
ings of fibrotic changes, such as in bronchial and alveolar
wall thickness, distortion of structure, and fibrous mass,
were recognized at each week (hematoxylin–eosin staining
and Masson’s trichrome staining, 340) (Figure 1, E-L)
compared with those in the saline group.were intratracheally administered saline or BLM (4.5 mg/kg). At 4, 8, 12,
matoxylin–eosin staining (A-H) and Masson’s trichrome staining (I-L). All
e-administered group. E-L, BLM-administered group. Each photograph is
rotic changes were recognized and alveolar structures were destroyed.





FIGURE 2. Evaluation of fibrotic change in the lung using numeric fi-
brotic score. Histologic examination in the left lung was performed by he-
matoxylin–eosin staining. Histologic score was determined by 1
pathologist and 1 surgeon as described in ‘‘Materials andMethods.’’ A, Sa-
line and BLM groups. Data are presented as mean  standard deviation in
each group of 6 animals. *P<.05 between saline and BLM groups. B, Con-
trol and implantation groups. Data are presented as mean  standard devi-
ation in the control group of 5 animals and the implantation group of 4
animals. BLM, Bleomycin; Imp, implantation.




SThe data of Ashcroft score are shown for both the saline
and BLM groups (Figure 2, A). In the BLM group, Ashcroft
scores at each of 4, 8, 12, and 16 weeks were similar,
namely, between 2.0 and 2.5, and there was no significant
difference in mean score. Pulmonary fibrosis was already
completed 4 weeks after BLM administration, and sponta-
neous remission did not occur for a long-term period rang-
ing over 16 weeks. In the saline group, fibrotic change was
not recognized at 4, 8, 12, or 16 weeks. At each week, Ash-
croft scores in the BLM group were significantly higher
than those in the saline group (P<.01).Evaluation of Fibrotic Change in the Lung of Control
and Implantation Groups Using the Ashcroft Score
In the control and implantation groups, various findings
of fibrotic changes like those in the BLM group were also
recognized in each week (not shown). Ashcroft score data
are shown for both control and implantation groups
(Figure 2, B). In the 2 groups, Ashcroft scores in recipient
lung field were similar, namely, between 2.0 and 2.5, and
there was no significant difference in mean scores between
each week. In addition, within each week, there was no1432 The Journal of Thoracic and Cardiovascular Sursignificant difference between the mean scores for both
groups. There was no therapeutic antifibrotic effect of
CyA administered to prevent immune response to GFP
protein.
Morphologic Changes of Implanted Fetal Lung
Tissues in Fibrotic Lung
Figure 3 shows morphologic changes of fetal lung tissues
at 1, 2, 4, 8, and 12 weeks after the implantation into fibrotic
lung. Implanted fetal lung tissues could survive in the
fibrotic lung. Although immunosuppression was performed
to prevent an immunoresponse to GFP protein in fetal lung
tissues, a few core necrotic lesions were present. With the
use of a fluorescence microscope, the recipient lung could
be clearly distinguished because of the luminescence of
grafts (Figure 3, A, B, D, E, G, H, J, K, M, N). The alveolar
spaces in implanted fetal lung were narrow at 1 and 2 weeks
(Figure 3, A-F), but expanded a little with the passage of
time. The connection between the recipient lungs and fetal
lungs was recognized morphologically, particularly in the
alveolar area (Figure 3, G-O). The epithelial cells in im-
planted fetal lungs changed from a pseudoglandular shape
to thinner and type I-like pneumocytes with the passage
of time.
Thyroid Transcription Factor-1 and Clara Cell
Secretory Protein Expression of the Graft With the
Passage of Time
One week after implantation, most epithelial cells ap-
peared to be cuboidal in shape, and the structures such as
the bud of terminal bronchiole and alveolar duct were
also recognized to some extent in the graft. TTF-1 was
well stained in the cuboidal cells. On the other hand,
CCSP was stained in the bronchiolar epithelial cells of the
bud of terminal bronchiole but was not stained in the cuboi-
dal cells (Figure 4,A). After 4 weeks, the implanted fetal tis-
sues further differentiated. Cuboidal cells decreased, and
bronchiole and alveolar duct mostly accounted for them.
The alveoli were partly covered by type I pneumocyte-
like cells. Both TTF-1 and CCSP were stained in the bron-
chiolar epithelial cells of the bronchiole and the alveolar
duct. Some of the alveolar cells in implanted lung were
slightly stained by TTF-1 but not by CCSP (Figure 4, B).
After 12 weeks, the alveolar spaces were filled with air
and implanted fetal tissues were recognized as structures
like postnatal lungs. CCSP was stained in the bronchial
epithelial cells, but TTF-1 expression was slightly stained
in the bronchial cells and alveolar cells (Figure 4, C).
DISCUSSION
BLM-induced pulmonary fibrosis in rodents has been
widely used as a good model exhibiting histologic findings
similar to human idiopathic pulmonary fibrosis.4 Various
experiments, such as the use of many antifibrotic agents,4gery c June 2012
FIGURE 3. Morphologic change of implanted fetal lung tissues in the BLM-induced fibrotic lung. Fetal lung tissues and surrounding area were examined
after 1 (A-C), 2 (D-F), 4 (G-I), 8 (J-L), and 12 (M-O) weeks. Each photograph is representative of 4 animals that were treated in the same way. Non-stained
specimens were observed by white light (A, D, G, J, M) and fluorescence (B, E, H, K, N) microscopy. Hematoxylin–eosin-stained specimens (C, F, I, L, O)
are shown at 1003magnification. Arrows show the border zones between injected and native tissues. Thin arrows show thewidened alveolar spaces in H, K,
and N. Bar ¼ 100.0 mm. H&E, Hematoxylin–eosin.
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FIGURE 4. Expression of TTF-1 and CCSP in implanted fetal lung tissues. Adjacent serial sections were stained for TTF-1 (Cy3; green fluorescence) or
CCSP (Alexa594; red fluorescence) with DAPI (blue fluorescence) counterstain at 1 (A), 4 (B), and 12 (C) weeks after implantation. A-C, 1003 magni-
fication.




Sintratracheal transplantation of alveolar type II cells,9 and
administration of bone marrow–derived stem cells,6 have
been tried to prevent fibrotic progression in the BLMmodel.
Chaudhary and colleagues17 indicated that the switch be-
tween inflammatory phase and fibrotic phase appears to oc-
cur at approximately day 9 in the rat BLM model. In
addition, continuous fibrotic changes result in deposition
of matrix and distortion of lung structure for as long as 28
or 35 days. In this study, we observed our fibrotic lung
model up to 36 weeks and demonstrated that fibrotic
changes continued over a long period of time with a single
administration of BLM by our method. The Ashcroft score
was 2.14  0.23 (n ¼ 6) at 36 weeks and showed no signif-
icant difference compared with those at 4, 8, 12, and 16
weeks. In our model, once fibrotic changes were completed,
spontaneous remission was not recognized. Accordingly,
this BLMmodel in rats is useful for observation over an ex-
tended period of time. In this study, CyAwas administered
to prevent an immune response to GFP protein in the control
and implantation groups. However, the Ashcroft score in the
BLM group was almost the same as those in the control and
implantation groups. CyA, which is one of the great variety
of compounds used in experimental attempts to show an
antifibrotic effect in the BLM model,18 is a drug tested in
clinical trials for idiopathic pulmonary fibrosis treatment.19
However, there was no antifibrotic effect of the administra-
tion of CyA in this study. We postulated that the reasons for
this were that the administered dose of CyAwas extremely
small and the time of initiation of administration of CyA
was 4 weeks after BLM administration, corresponding to
the fibrotic phase in this study. In general, antifibrotic agents
are administered in the anti-inflammatory phase.
The current study demonstrated that fetal lung tissues
could also survive, grow further, and differentiate in the
BLM-induced fibrotic lungs, as we previously reported
the same phenomenon in normal adult lungs.11 In this pre-
vious study, we used inbred animals as the donors and recip-
ients to avoid immune responses. However, in this study, we
used fetal lung tissues of GFP rats as the donor tissues. As1434 The Journal of Thoracic and Cardiovascular Sura result, we could more clearly distinguish the border zones
between injected and native tissues. Although it was conse-
quently necessary to use CyA as an immunosuppressive
agent for GFP protein, its dose was small and there was
no effect on the engraftment.
At 1 to 2 weeks after implantation, the morphology of the
grafts was similar to that in the pseudoglandular stage of
fetal rat lung and epithelial cells were mainly composed
of cuboidal cells. However, at 4 and 8 to 12 weeks, alveolar
units were formed in some lesions and epithelial cells were
mainly composed of type I pneumocyte-like cells. These
phenomena were similar to changes over time as described
in a previous report.11 However, air spaces of grafts im-
planted in fibrotic lungs were clearly narrow compared
with those in normal lungs, although they expanded slightly
at 4, 8, and 12 weeks. One cause of this might be low com-
pliance of a recipient’s lung because of BLM-induced
fibrotic lung. Moreover, these results might be partly due
to less mechanical forces in the recipient lungs. We previ-
ously demonstrated that mechanical forces by partial lung
resection might facilitate proliferation and maturation of
implanted fetal tissues.11 In this study, partial removal of
the left lung was only performed as closure of an inlet for
implantation on a recipient’s lung to prevent air leakage
without removal of the postcaval lobe of the recipient’s
lung. Although air spaces were narrow owing to low com-
pliance of the lung and less mechanical forces, survival
and differentiation of grafts in the fibrotic lungs might be
considered one important aspect of this study.
TTF-1 is a member of the Nkx2 family of homeodomain-
containing proteins expressed in forebrain, thyroid, and
lung. In the lung, TTF-1 plays a critical role in the regula-
tion of lung morphogenesis, epithelial cell differentiation,
and expression of genes on which perinatal respiratory
adaptation depends.20,21 TTF-1 is expressed in respiratory
epithelial cells at all stages throughout lung morphogenesis.
In addition, in the postnatal lung, TTF-1 is also expressed
primarily in alveolar type II epithelial cells.22 On the other
hand, Clara cells have been shown to be the progenitors ofgery c June 2012




Sciliated cells in the bronchioles and to be critical for epithe-
lial renewal after progenitor cell depletion.21,23 CCSP is
expressed in Clara cells and regulated by TTF-1.24 In this
study, TTF-1 was well stained in most cuboidal cells and
epithelial cells of terminal bronchiole in the graft at
1 week. Later, the TTF-1 expression was mainly recognized
in bronchial epithelial cells but was also recognized in alve-
olar epithelial cells through the passage of time from 4 to
12 weeks. In addition, the CCSP expression was recognized
in only bronchial epithelial cells. On the basis of the TTF-1
and CCSP expression data, these results resemble the pat-
tern in the process of normal lung morphogenesis. There-
fore, in recipient lungs, the graft may pass through the
normal fetal rat lung morphogenetic course.
Fetal rat lung tissue has (1) great potential for further
growth, (2) excellent potential for differentiation and prolif-
eration, and (3) mesenchymal tissue as a suitable scaffold.12
The results of this study might be dependent on these char-
acteristics of fetal lung tissue. However, this study demon-
strated the survival and differentiation of implanted fetal
lung tissues in BLM-induced completed fibrotic lung. In
previous studies, the use of many anti-inflammatory drugs4
and the administration of bone marrow–derived stem cells,6
alveolar type II cells,9 and others were methods to prevent
the fibrotic process. Our study can be considered to show
another new regenerative approach using fetal rat lung tis-
sue for already completely fibrotic lung. Furthermore, we
could demonstrate that implanted fetal lung tissues might
follow the normal fetal rat lung morphogenetic course in re-
cipient lung. This phenomenon shows a part of the mecha-
nism of differentiation of implanted fetal lung tissues.
However, further research on the morphogenetic mecha-
nism is needed. This could lead to the development of ap-
propriate techniques to induce implanted fetal lung tissue
to become mature lung and increase the donors freely. On
the other hand, we are left with the issues of whether im-
plantation of fetal lung tissue can improve respiratory func-
tion in fibrotic lung model and which cells of the fetal rat
lung tissue can play key roles in the survival and differenti-
ation. In addition, our experimental model should be ap-
plied to large animals and allografts. Furthermore, ethical
concern might remain about the use of fetal lung tissue to
treat adult human diseases. Nevertheless, we believe that
fetal lung tissue is a potentially useful option for investigat-
ing lung regeneration.CONCLUSIONS
Fetal rat lung fragments survived and differentiated in
BLM-induced completely fibrotic lung.The Journal of Thoracic and CarThe authors thank Eiji Kobayashi, Division of Development of
Advanced Treatment, Center for Development of Advanced Med-
ical Technology, Jichi Medical University, for providing GFP
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